Ocular Therapeutix (OCUL) Earning Somewhat Positive Media Coverage, Study Finds
Media headlines about Ocular Therapeutix (NASDAQ:OCUL) have been trending somewhat positive on Wednesday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.1144361624305 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several equities analysts have recently weighed in on OCUL shares. Guggenheim initiated coverage on Ocular Therapeutix in a report on Monday, October 23rd. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, November 8th. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. BTIG Research upgraded Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research report on Friday, January 19th. Finally, ValuEngine raised shares of Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.67.
Shares of Ocular Therapeutix (NASDAQ OCUL) traded up $0.01 during mid-day trading on Wednesday, reaching $5.18. 233,951 shares of the company traded hands, compared to its average volume of 601,791. The stock has a market capitalization of $181.15, a price-to-earnings ratio of -2.27 and a beta of 1.53. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39. Ocular Therapeutix has a 12 month low of $3.30 and a 12 month high of $11.79.
In other Ocular Therapeutix news, Chairman Amarpreet Sawhney acquired 19,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average cost of $5.18 per share, with a total value of $98,420.00. Following the completion of the acquisition, the chairman now directly owns 696,390 shares in the company, valued at approximately $3,607,300.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel M. Bollag acquired 24,700 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average cost of $3.93 per share, for a total transaction of $97,071.00. Following the completion of the acquisition, the insider now owns 24,700 shares of the company’s stock, valued at $97,071. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 69,500 shares of company stock worth $304,781. 26.10% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Ocular Therapeutix (OCUL) Earning Somewhat Positive Media Coverage, Study Finds” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/ocular-therapeutix-ocul-earning-somewhat-positive-media-coverage-study-finds/1850833.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.